| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1036 | |
| Phytochemical name or plant extracts | (4α,5α,8β,10β)-4,10-dihydroxy-1,11(13)-guaidien-12,8-olide | |
| PMID | 30580030 | |
| Literature evidence | Compound 4 exhibited strong and selective cell growth inhibition against HT-29 with viability 20.99% and was identified as a promising compound with high selectivity between cancer cells and normal human lung cells (BEAS-2B), especially against HT-29 (IC50 = 12.2 μg/mL) compared to that of cisplatin. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Sesquiterpene lactone | |
| Source of phytochemicals or plant Extracts | Chrysophthalmum montanum | |
| Geographical availability | Southeastern, and Eastern parts of Turkey | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer, Colon cancer, Lung cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 26.5±0.6 µg/mL against MCF-7 | |
| Potency | In our study, we found that compound 4 has a low cytotoxicity against MCF-7 with IC50 value of >100 µg/mL by SRB assay | |
| Cell line/ mice model | MCF-7, MDA-MB 231, HT-29, PC3 | |
| Additional information | Compound 4 exhibited strong and selective cell growth inhibition against HT-29 with viability 20.99% and was identified as a promising compound with high selectivity between cancer cells and normal human lung cells (BEAS-2B), especially against HT-29 (IC50 = 12.2 μg/mL) compared to that of cisplatin. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://doi.org/10.1016/j.phytol.2020.01.003 | |
| Safety | NA |